Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: A survey of the Japan Lymphoma Radiation Therapy Group

被引:24
作者
Oguchi, M
Ikeda, H
Isobe, K
Hirota, S
Hasegawa, M
Nakamura, K
Sasai, K
Hayabuchi, N
机构
[1] Shinshu Univ, Sch Med, Dept Radiol, Matsumoto, Nagano 390, Japan
[2] Natl Canc Ctr Hosp E, Dept Radiat Oncol, Koshiwa, Japan
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2000年 / 48卷 / 01期
关键词
chemotherapy; non-Hodgkin's lymphoma; prognostic factor; radiation therapy; tumor bulk;
D O I
10.1016/S0360-3016(00)00480-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To identify the prognostic factors that specifically predict survival rates of patients with localized aggressive non-Hodgkin's lymphoma (NHL). Methods and Materials: The survey was carried out at 25 radiation oncology institutions in Japan in 1998. The 5-year event;free (EFS) and overall survival rates (OAS) were calculated, and univariate and multivariate analyses were done to identify which of the following factors, namely, gender, age, performance status (PS), serum lactate dehydrogenase (LDH) level, Stage (I vs. II), tumor bulk (maximum diameter), and treatment, were significant from the viewpoint of prognosis. Results: A total of 1141 patients with Stage I and LI NHL were treated by the Japanese Lymphoma Radiation Therapy Group between 1988 and 1992. Of them, 787 patients, who were treated using definitive radiotherapy with or without chemotherapy for intermediate- and high-grade lymphomas in working formulation, constituted the core of this study. Primary tumors arose mainly from extranodal organs (71%) in the head and neck (Waldeyer's ring: 36% and sinonasal cavities: 9%). The factors associated with poorer prognosis were age over 60 years old (p < 0.0001), radiation therapy alone (p < 0.0001), PS = 2-4 (p = 0.0011), (sex male,p = 0.0078), a bulky tumor more than 6 cm in maximum diameter (p = 0.0088), elevated LDH (p = 0.0117), and stage II (p = 0.0642). A median dose of 42 Gy was delivered mainly to the involved fields. Short-course chemotherapy was provided in 549 (70%) patients. The 5-year OAS and EFS rates for an patients were 71% and 67%, respectively. According to the stage-modified International Prognostic Index, the 5-year EFS of the patients with risk factors from 0 to 1 was 76%, 61% for patients with two risk factors, and 26% for patients with three or more risk factors. Conclusion: Extranodal presentation, especially Waldeyer's ring and sinonasal cavities, is encountered more frequently in Japan than in Western countries. Tumor hulk is an important prognostic factor in patients with localized aggressive extranodal NHL. Short course chemotherapy followed by radiation therapy was associated with prolonged survival in patients with localized aggressive NHLs of extranodal origin and 0-1 risk factor. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:161 / 168
页数:8
相关论文
共 25 条
[1]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[2]   BRIEF CHEMOTHERAPY AND INVOLVED FIELD RADIATION-THERAPY FOR LIMITED-STAGE, HISTOLOGICALLY AGGRESSIVE LYMPHOMA [J].
CONNORS, JM ;
KLIMO, P ;
FAIREY, RN ;
VOSS, N .
ANNALS OF INTERNAL MEDICINE, 1987, 107 (01) :25-30
[3]   Chemoradiotherapy for localized non-Hodgkins lymphoma [J].
Cosset, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (01) :44-45
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]   TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[6]   COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA [J].
FISHER, RI ;
GAYNOR, ER ;
DAHLBERG, S ;
OKEN, MM ;
GROGAN, TM ;
MIZE, EM ;
GLICK, JH ;
COLTMAN, CA ;
MILLER, TP .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (14) :1002-1006
[7]   SIGNIFICANCE OF TUMOR SIZE AND RADIATION-DOSE TO LOCAL-CONTROL IN STAGE I-III DIFFUSE LARGE-CELL LYMPHOMA TREATED WITH CHOP-BLEO AND RADIATION [J].
FULLER, LM ;
KRASIN, MJ ;
VELASQUEZ, WS ;
ALLEN, PK ;
MCLAUGHLIN, P ;
RODRIGUEZ, MA ;
HAGEMEISTER, FB ;
SWAN, F ;
CABANILLAS, F ;
PALMER, JL ;
COX, JD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (01) :3-11
[8]  
Glick JH., 1995, P AN M AM SOC CLIN, V14, P391
[9]   LONG-TERM FOLLOW-UP AND ANALYSIS FOR PROGNOSTIC FACTORS FOR PATIENTS WITH LIMITED-STAGE DIFFUSE LARGE-CELL LYMPHOMA TREATED WITH INITIAL CHEMOTHERAPY WITH OR WITHOUT ADJUVANT RADIOTHERAPY [J].
JONES, SE ;
MILLER, TP ;
CONNORS, JM .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (09) :1186-1191
[10]   FACTORS PREDICTING SURVIVAL IN ADULTS WITH STAGE I AND II LARGE-CELL LYMPHOMA TREATED WITH PRIMARY RADIATION-THERAPY [J].
KAMINSKI, MS ;
COLEMAN, CN ;
COLBY, TV ;
COX, RS ;
ROSENBERG, SA .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) :747-756